Hungarian drugmaker Humet is currently negotiating with potentialpartners with regards to selling its products in the USA. The company has said that it intends to meet an increase in orders through agreements with US partners and is in talks with five groups over a sales strategy for Humet drugs in the the country. Humet's vice president, Barnabas Nagy, said that it had meanwhile agreed with its UK partner to co-ordinate sales in Europe. Current manufacturing capacity allows Humet to produce 140,000 units per month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze